Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

XyloCor Therapeutics Reported Positive Safety and Efficacy Results of XC001 Novel Gene Therapy for Refractory Angina

January 27, 2023 0

XyloCor Therapeutics Announced Positive Results for XC001 XyloCor Therapeutics announced the completion of the Phase 2 portion of its Phase 1/2 clinical trial (EXACT) designed to assess the safety and preliminary evidence of efficacy of lead gene therapy candidate XC001 (encoberminogene rezmadenovec) in patients with refractory angina. The EXACT clinical trial met both safety and efficacy objectives. There were no safety issues …

From bluebird bio: FDA Accelerated Approval for SKYSONA® Gene Therapy...

Intellia Therapeutics to Present Data from Clinical Trial of NTLA-2002...

Hutchmed: Treating Advanced Metastatic Colorectal Cancer and Other Treatment Resistant...

Avista Therapeutics Partners with Roche to Develop Advanced AAV Gene...

CytomX Therapeutics Provided an Important Strategic Update

Insilico Medicine: Identifying Multiple Novel Therapeutic Targets for ALS AI-driven...

Vertex Pharmaceuticals and Type 1 Diabetes

An Important Reminder from Vir Biotechnology

Eisai and Biogen: Lecanemab for the Treament of Early Alzheimer’s...

Sunshine Biopharma’s New mRNA Therapeutics Killed Cancer Cells with Little...

Reata Pharmaceuticals Completed Rolling NDA Submission of Omaveloxolone for Friedreich’s...

Intellia Therapeutics Statement on Recent U.S. Patent and Trademark Office...

These Dangerous World Circumstances and the Prohost Portfolio

The FDA Authorized Emergency Use of Pfizer Paxlovid Pills Against...

The FDA Cleared the IND for Erasca Inc Product ERAS-801...

Takeda Pharmaceutical Product LIVTENCITY Granted Approval by the FDA

Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9...

No Evidence of Data Manipulation in Technical Paper Foundational to...

Gilead Sciences and Merck Initiate Phase 2 Study Evaluating Lenacapavir...

Impacting News

CytomX: Why Does Good News from This Firm Cause Its Stock to Move South Instead of North?

February 2, 2023 0

CytomX Therapeutics We posted several articles that brought good news from CytomX Therapeutics (CTMX), yet the …

TG Therapeutics Launched FDA Approved Product BRIUMVI™ for Patients with Relapsing Forms of MS

January 27, 2023 0

TG Therapeutics TG Therapeutics (TGTX) is a commercial stage, biopharmaceutical company developing and commercializing novel treatments for …

Jazz Pharmaceuticals and Zymeworks Product Zanidatamab Advance the Treatment of HER2-expressing mGA

January 20, 2023 0

Jazz Pharmaceuticals and Zymeworks Inc Announce Results of Zanidatamab Jazz Pharmaceuticals (JAZZ) and Zymeworks Inc. (ZYME)

Ionis and Royalty Pharma Enter into a Royalty Agreement for Up to $1.1B

January 13, 2023 0

Ionis Pharmaceuticals and Royalty Pharma Ionis Pharmaceuticals (IONS) and Royalty Pharma plc (RPRX) announced that Royalty Pharma has …

Why Investors Have Enthusiasm for CureVac N.V.

January 10, 2023 0

CureVac N.V. in the News CureVac N.V. (CVAC) announced that after more than 10 years as …

A Note To Our Followers

December 23, 2022 2

Dear Friends and Followers, We confirm our optimism towards the future biotech firms that we selected …

Trick or Trade

Xenon Pharmaceuticals: A Newly Selected Clinical-Stage Firm. See Also: Recently Selected Clinical Stage Firms

February 7, 2023 0

Xenon Pharmaceuticals Xenon Pharmaceuticals (XENE) - a clinical stage biopharmaceutical company developing novel treatments aimed at improving …

Could We Soon Have a Specific Treatment for the Rare Disease IgA Nephritis?

February 2, 2023 0

It's Time to Remind About Travere Therapeutics The time has come to remind that the U.S. …

Stocks Outperforming Today

January 5, 2023 0

January 5, 2023 In Today's Down Market the stocks that are outperforming are as follows: Reata …

Promising Stocks in the First Two Trading Days of 2023

January 4, 2023 0

The Stock Market in the New Year It is still too early to tell how the …

What We Learned This Morning

December 13, 2022 0

Dear Subscribers, This is what we learned this morning: FTX: we learned about the arrest of …

Searching for Biotech Firms with Novel Drugs That Reached Clinical-Stage or Were Granted Early Fast Track Designation

October 28, 2022 0

Searching for Biotech Firms The search is for firms biotech firms that have reached clinical stage …

Today’s Highlights

Merck: KEYTRUDA Plus Chemo as First-Line Treatment for Stage III-IV or Recurrent Endometrial Carcinoma

February 3, 2023 0

Merck KEYTRUDA Announcement Merck (MRK) announced today that Phase 3 NRG-GY018 trial evaluating KEYTRUDA in combination …

Shoreline Biosciences to Acquire Editas Medicine’s iNK cell franchise

January 19, 2023 0

Shoreline Biosciences to Acquire Editas Medicine’s iNK cell franchise Editas Medicine, Inc. (EDIT), announced that it has …

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

January 5, 2023 1

CytomX and Moderna in the NEWS On January 05, 2023, CytomX Therapeutics (CTMX) and Moderna Inc (MRNA) announced a collaboration …

Why Kala Pharmaceuticals Stock is Soaring

December 28, 2022 0

Kala Pharmaceuticals Kala Pharmaceuticals (KALA) announced today that the U.S. FDA has accepted the investigational new drug …

Madrigal Pharmaceuticals and Akero Therapeutics: After Having No Treatment for NASH, We Now Have Two Products Expected to be Approved

December 19, 2022 0

Treatments for NASH Madrigal Pharmaceuticals (MDGL) is the second company after Akero Therapeutics (AKRO) to . …